Exploring the role of MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia
“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]”
BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”
Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) ...















